Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALTS

ALT5 Sigma Corp.

Sep 13 • 04:00PM ET

2.18

Dollar change -0.09
Percentage change -3.96	%

Technology • Software - Application • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VXF VTI IWC BSVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.19	Insider Own	3.79%	Shs Outstand	12.77M	Perf Week	3.81%
Market Cap	27.84M	Forward P/E	-	EPS next Y	-	Insider Trans	1.04%	Shs Float	11.88M	Perf Month	27.49%
Income	-16.00M	PEG	-	EPS next Q	-	Inst Own	1.78%	Short Float	3.02%	Perf Quarter	-9.54%
Sales	2.17M	P/S	12.83	EPS this Y	-	Inst Trans	-5.17%	Short Ratio	1.25	Perf Half Y	-24.31%
Book/sh	0.51	P/B	4.30	EPS next Y	-	ROA	-32.97%	Short Interest	0.36M	Perf Year	411.14%
Cash/sh	0.45	P/C	4.83	EPS next 5Y	-	ROE	-65.72%	52W Range	0.22 - 5.26	Perf YTD	292.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.21%	ROI	-51.12%	52W High	-58.56%	Beta	2.23
Dividend TTM	-	Quick Ratio	0.73	Sales past 5Y	-17.99%	Gross Margin	-44.44%	52W Low	889.11%	ATR (14)	0.31
Dividend Ex-Date	Apr 01, 2022	Current Ratio	0.73	EPS Y/Y TTM	36.23%	Oper. Margin	-336.98%	RSI (14)	49.67	Volatility	13.67% 15.50%
Employees	5	Debt/Eq	0.39	Sales Y/Y TTM	-89.02%	Profit Margin	-737.57%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.17	EPS Q/Q	108.63%	Payout	-	Rel Volume	1.07	Prev Close	2.27
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	285.72K	Price	2.18
SMA20	-6.84%	SMA50	5.80%	SMA200	8.77%	Trades		Volume	304,782	Change	-3.96%

Sep-10-24 11:00AM	ALT5 Sigma Reports 104% Year-Over-Year Increase in Transaction Volume to Over US$1.250 Billion for First Eight Months of 2024 (ACCESSWIRE)
Sep-09-24 08:00AM	ALT5 Sigma to Exhibit at iFX Bangkok September 16-18, 2024 (ACCESSWIRE)
Aug-26-24 08:45AM	ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer (ACCESSWIRE) -6.69%
Aug-23-24 11:00AM	ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024 (ACCESSWIRE)
Aug-19-24 06:30PM	ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024 (ACCESSWIRE) +28.63% -8.22%
08:30AM	Loading…
Aug-13-24 08:30AM	ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024 (ACCESSWIRE) -5.13%
Jul-25-24 08:30AM	ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024 (ACCESSWIRE)

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tassiopoulos Peter	Chief Executive Officer	Sep 09 '24	Buy	2.06	5,000	10,278	420,000	Sep 11 11:57 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALTS

ALT5 Sigma Corp.

Upgrade your FINVIZ experience